On Friday, it has been reported by Ranbaxy Laboratories, which is considered as India's largest drug maker that its shares have been down by 2.51% in the second quarter. They have met a 25% fall in their net profit during the period.

Recently, it has come into knowledge that this Gurgaon- based company, in order to look out for a solution for its regulatory issues, is working with the US authorities of Food and Drug Administration and the Department of Justice. And as told by the Company, these negotiations with the regulators are doing well.

As told by Arun Sawhney, who is the managing director of Ranbaxy, "We remain optimistic going ahead to protect our business and resolve the issue".

Three months back, the Company has just launched a potential blockbuster in the world's largest drug market.

According to the report, last year, for the same quarter, the Company reported to have consolidated sales for around Rs. 2,095 crore, which this year has been reported as Rs 2,059 crore. This means despite of a foreign exchange gain of $25 million against a loss of $51 million last year, this quarter, the consolidated sales have dropped drastically.